Back

Arrowhead reports 72% PCSK9 and 88% APOC3 reductions in trial

Verifying
  • Arrowhead Pharmaceuticals released interim topline data from the ARO-DIMER-PA Phase 1/2a trial.
  • ARO-DIMER-PA reduced serum PCSK9 by 72% and APOC3 by 88% at mean maximum single dose.
  • Zodasiran is being studied in the global Phase 3 YOSEMITE trial for homozygous familial hypercholesterolemia.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.